🔴 BioXcel Therapeutics is trading 12.9% down in pre-market after second-quarter results missed expectations

BioXcel Therapeutics is trading 12.9% down at $0.78 after its August 17, 2026, second-quarter results missed expectations.

• EPS was -$0.490 versus -$0.423 estimated; revenue was $182K versus $403.32K expected.
• The company reported $13.8 million in cash and $17.9 million in first-half operating cash use, intensifying liquidity concerns.
• Premarket volume was 103.07K shares, indicating active trading.